Gene expression profiling of recipient immune cells induced by 7 × 19 CAR-T cell dosing in a syngeneic mouse model
PLOS One · 17.07.2026 · 21 (7) · e0352813
DOI: 10.1371/journal.pone.0352813 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 17.07.2026. Verfasst von Yo Muraki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Drug Discovery Unit Japan, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan. Hauptthemen laut MEDLINE: Gene Expression Profiling, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noile-Immune Biotech Inc, Takeda Pharmaceutical Company Limited, Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy is effective for hematologic malignancies; however, the response of solid tumors is limited because of the immunosuppressive tumor microenvironment, antigen heterogeneity, and lack of persistence of transferred T cells. To overcome these challenges, CAR-T cells expressing interleukin-7 and CC chemokine ligand 19 (7 × 19 CAR-T) were generated to achieve potent antitumor efficacy through the recruitment and proliferation of CAR-T cells and endogenous immune cells. To elucidate the underlying mechanism of 7 × 19 CAR-T cells against solid tumors, we analyzed the cellular composition and gene expression profiles of host immune cells following CAR-T cell infusion in a murine solid tumor model. Antihuman CD20 7 × 19 CAR-T cells were prepared using Thy 1.1 congenic mice and administered to C57BL/6N mice bearing subcutaneous MC38 tumors expressing human CD20. The tumors were harvested 4 days postinfusion to capture early immune responses before overt tumor regression. CD90.1- recipient immune cells were subjected to flow cytometry analysis, and transcriptomic changes were determined using AmpliSeq and single-cell RNA seq. An increase in recipient CD8 + T cells and macrophages was observed in the tumor of mice treated with 7 × 19 CAR-T cells, but not with conventional CAR-T. The expression of chemokines and genes associated with the inflammatory pathway was upregulated only in recipient immune cells of the 7 × 19 CAR-T-treated mice. Single-cell RNA-seq analysis revealed upregulation of pro-inflammatory genes and chemokines in the dendritic cell and monocyte/macrophage populations. These results indicate that 7 × 19 CAR-T cells initiate the early recruitment and activation of host immune cells, which contributes to their superior antitumor activity compared with conventional CAR-T cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oncology Drug Discovery Unit Japan, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
- Noile-Immune Biotech Inc., Minato-ku, Tokyo, Japan.
- Research Institute for Cell Design Medical Science, Yamaguchi University, Ube City, Yamaguchi, Japan.
- Department of Immunology, Yamaguchi University Graduate School of Medicine, Ube City, Yamaguchi, Japan.
ORCID-Profile: Yo Muraki, Yuumi Okuzono, Chihiro Take
Förderung
- Noile-Immune Biotech Inc
- Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company
- Noile-Immune Biotech Inc.
Zitieren
APA
Muraki, Y., Okuzono, Y., Kurisu, R., Abiru, A., Sakoda, Y., Tamada, K., & Take, C. (2026). Gene expression profiling of recipient immune cells induced by 7 × 19 CAR-T cell dosing in a syngeneic mouse model. PLOS One, 21(7), e0352813. https://doi.org/10.1371/journal.pone.0352813
Vancouver
Muraki Y, Okuzono Y, Kurisu R, Abiru A, Sakoda Y, Tamada K, et al. Gene expression profiling of recipient immune cells induced by 7 × 19 CAR-T cell dosing in a syngeneic mouse model. PLOS One. 2026;21(7):e0352813. doi:10.1371/journal.pone.0352813
BibTeX
@article{Muraki2026,
author = {Muraki, Yo and Okuzono, Yuumi and Kurisu, Rina and Abiru, Akiko and Sakoda, Yukimi and Tamada, Koji and Take, Chihiro},
title = {Gene expression profiling of recipient immune cells induced by 7 × 19 CAR-T cell dosing in a syngeneic mouse model},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0352813},
doi = {10.1371/journal.pone.0352813}
}
EUVIMED